Rezolute, Inc. (filing identifies AntriaBio, Inc.) — 10-K summary
Period and entity: The supplied filing is AntriaBio, Inc.’s annual report for the fiscal year ended June 30, 2015, filed September 28, 2015. This does not match the request metadata identifying Rezolute, Inc. and “2014 Q4”; verify the issuer and reporting period before relying on this summary.
Business context
AntriaBio was a preclinical biopharmaceutical company developing sustained-release injectable therapies. Its lead candidate, AB101, was a proposed once-weekly basal insulin for Type 1 and Type 2 diabetes. AB301, a proposed once-weekly combination of a GLP-1 agonist and AB101, was added to the pipeline in September 2015. The company had no approved products or revenue.
Financial results and liquidity
| Metric | FY ended June 30, 2015 | FY ended June 30, 2014 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.70 million | $34,317 |
| General and administrative expense | $6.00 million | $5.14 million |
| Net loss | $11.36 million | $9.73 million |
| Net loss per share | $0.54 | $1.04 |
| Cash used in operating activities | $7.08 million | $3.17 million |
| Cash used in investing activities | $3.61 million | $0.83 million |
| Cash provided by financing activities | $10.04 million | $9.93 million |
- At June 30, 2015, cash was $5.28 million, restricted cash was $450,167, and working capital was approximately $4.41 million. Total assets were $11.26 million; total liabilities were $2.21 million; stockholders’ equity was $9.05 million.
- Operating expenses more than doubled, principally as the company began substantial R&D, built out its facilities, and hired staff. The net loss increased, while loss per share declined due to a higher weighted-average share count.
- Net loss included $662,723 of derivative losses. FY2014 interest expense was unusually high at $4.23 million, largely reflecting amortization of a convertible-debt beneficial conversion feature; FY2015 interest expense was $6,729.
- The company raised equity in FY2015, reporting $11.18 million in gross proceeds and approximately $10.1 million in net proceeds from private placements. Shares outstanding increased to 24,338,219 by June 30, 2015. Warrants and options create substantial potential dilution.
- Debt included $60,000 of convertible notes, which had matured and were due, accruing interest at 8%. The balance sheet also included lease payables. Contractual operating and capital lease obligations totaled approximately $1.96 million.
- No revenue or operating margin was reported; the company remained loss-making and had no commercial product.
Outlook, material developments, and risks
- Management expected to need approximately $15–20 million in additional capital through calendar 2016; the MD&A also cites approximately $15 million to fund objectives through year-end 2016. Management said available resources were insufficient to fund operations through 2016. The auditor’s report and the filing state that substantial doubt existed about the company’s ability to continue as a going concern.
- FDA feedback requiring at least six months of stability data for AB101 drug substance, together with delays completing the cGMP suite, pushed the expected IND filing to the end of the second quarter of 2016. Clinical commencement was planned after FDA acceptance. These are management expectations, not guaranteed milestones.
- Six-week repeat-dose toxicology studies in dogs and rats had been completed, with analysis and reports still underway. AB101 had not entered human trials. Animal findings are not evidence of clinical efficacy or safety.
- The cGMP suite was reported as 90% complete as of September 25, 2015, with completion expected in October 2015; cGMP clinical material was not expected until the first quarter of 2016. AB301 remained in preclinical development.
- Key risks include financing availability and dilution, clinical and regulatory failure or delay, manufacturing readiness and third-party supply dependence, competition from larger pharmaceutical companies, uncertain market acceptance and reimbursement, and intellectual-property protection.
- Disclosure controls were deemed ineffective, and management identified a material weakness: the chief accounting officer could initiate and complete ledger transactions and override controls. Remediation efforts were underway but not assured.
- The filing reported no pending or threatened lawsuits expected to have a material effect and no off-balance-sheet arrangements. It also reported no product-liability insurance at the time, before clinical trials began.
Important facts to verify
- Confirm whether this AntriaBio FY2015 filing is the intended filing, rather than a Rezolute, Inc. filing or a 2014 Q4 report.
- Check subsequent filings for actual financing raised, cash runway, and whether the company met the stated capital requirement.
- Verify completion and validation of the cGMP suite, stability-data results, IND submission and FDA response, and the timing and status of AB101 clinical studies.
- Review the full financial statements and subsequent disclosures for the matured $60,000 notes, lease commitments, warrant liabilities, and any further dilution.
- Track remediation of the material weakness and any changes in auditor going-concern language.